Quantbot Technologies LP Has $3.72 Million Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Quantbot Technologies LP increased its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 389.3% in the third quarter, Holdings Channel reports. The firm owned 15,705 shares of the medical research company’s stock after buying an additional 12,495 shares during the quarter. Quantbot Technologies LP’s holdings in IQVIA were worth $3,722,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Versant Capital Management Inc grew its stake in IQVIA by 733.3% in the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after acquiring an additional 110 shares during the period. Opal Wealth Advisors LLC bought a new stake in shares of IQVIA in the second quarter valued at about $27,000. Capital Performance Advisors LLP bought a new stake in shares of IQVIA in the third quarter valued at about $27,000. Park Place Capital Corp bought a new stake in shares of IQVIA in the third quarter valued at about $28,000. Finally, Itau Unibanco Holding S.A. bought a new stake in shares of IQVIA in the second quarter valued at about $29,000. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Price Performance

IQVIA stock opened at $201.24 on Wednesday. The stock’s fifty day moving average price is $221.18 and its two-hundred day moving average price is $226.75. IQVIA Holdings Inc. has a one year low of $187.62 and a one year high of $261.73. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. The firm has a market cap of $36.53 billion, a PE ratio of 26.41, a price-to-earnings-growth ratio of 2.10 and a beta of 1.51.

Wall Street Analyst Weigh In

IQV has been the topic of several analyst reports. Leerink Partners reiterated an “outperform” rating and set a $248.00 target price (down previously from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. BTIG Research dropped their target price on IQVIA from $290.00 to $260.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Morgan Stanley dropped their target price on IQVIA from $280.00 to $265.00 and set an “overweight” rating on the stock in a report on Monday, November 4th. The Goldman Sachs Group dropped their target price on IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Finally, TD Cowen dropped their price objective on IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Four equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, IQVIA currently has a consensus rating of “Moderate Buy” and a consensus price target of $256.50.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.